Literature DB >> 28526916

[Salvage radiotherapy with antiandrogen therapy after prostatectomy : Significant overall survival benefit compared to radiotherapy alone].

Gregor Goldner1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28526916     DOI： 10.1007/s00066-017-1148-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  2 in total

1.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Authors:  William U Shipley; Wendy Seiferheld; Himanshu R Lukka; Pierre P Major; Niall M Heney; David J Grignon; Oliver Sartor; Maltibehn P Patel; Jean-Paul Bahary; Anthony L Zietman; Thomas M Pisansky; Kenneth L Zeitzer; Colleen A F Lawton; Felix Y Feng; Richard D Lovett; Alexander G Balogh; Luis Souhami; Seth A Rosenthal; Kevin J Kerlin; James J Dignam; Stephanie L Pugh; Howard M Sandler
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

2.  Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Authors:  Christian Carrie; Ali Hasbini; Guy de Laroche; Pierre Richaud; Stéphane Guerif; Igor Latorzeff; Stéphane Supiot; Mathieu Bosset; Jean-Léon Lagrange; Véronique Beckendorf; François Lesaunier; Bernard Dubray; Jean-Philippe Wagner; Tan Dat N'Guyen; Jean-Philippe Suchaud; Gilles Créhange; Nicolas Barbier; Muriel Habibian; Céline Ferlay; Philippe Fourneret; Alain Ruffion; Sophie Dussart
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.